Advertisement

Topics

Latest "Alembic Limited" News Stories

16:20 EST 9th December 2018 | BioPortfolio

Here are the most relevant search results for "Alembic Limited" found in our extensive news archives from over 250 global news sources.

More Information about Alembic Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Alembic Limited for you to read. Along with our medical data and news we also list Alembic Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of Alembic Limited Companies for you to search.

Showing "Alembic Limited" News Articles 1–25 of 316

Relevant

Alembic Pharmaceuticals net up by 36% in Q1

Alembic Pharmaceuticals, a Vadodara based Rs.3,100 crore plus pharma major, has posted net profit growth of 35.7 per cent during the first quarter ended June 2018 to Rs.90.47 crore from Rs.66.67 crore in the


FDA approves Alembic's major depressive disorder tablets

The FDA has approved Indian drugmaker Alembic Pharmaceuticals' abbreviated new drug application for major depressive disorder -More- 

Alembic gains FDA tentative approval for generic Latisse


Swift And Nimble – Alembic Laps Up US Valsartan Windfall In Q2

Alembic moved fast and seized supply opportunities for valsartan, the hypertension drug that has seen shortages in the US, though...   

Alembic gets tentative FDA nod for generic Brilinta tablets

FDA approves Alembic’s generic Wellbutrin

Plenty Of Potential For Roche's Entrectinib Despite Lack Of ESMO Enthusiasm

Roche's up and down ESMO is best summed up by the response to data presented on its personalised cancer med...   

Positive Phase III For Darolutamide In Prostate Cancer Could Improve Options For Orion

Top-line results from the Phase III ARAMIS study indicate the next-generation oral androgen receptor antagonist, darolutamide, has met its primary...   

Deal Watch: Alexion Encouraged By RNAi Developments, Partners With Dicerna

Alexion thinks Dicerna’s RNAi technology could address complement-mediated conditions further upstream from antibodies like Soliris. AbbVie takes over CF collaboration...  

Quotient Limited Announces Details of Investor Day

JERSEY, Channel Islands, July 16, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ headquarters in New York earlier today. Following the recent announcement of positive field trial data in a European field trial, the Company met earlier today with investors and analysts at NASDAQ’...

Quotient Limited to Host Investor Day on July 16, 2018

JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July 16, 2018 from 9:00am – 1:00pm ET, in New York, NY. At the event, Franz Walt, Chief Executive Officer of Quotient Limited, along with other members of the management team, will provide a briefing on ...

Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data

JERSEY, Channel Islands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation (V&V) concordance data for its initial MosaiQ™ Serological Disease Screening (SDS) Microarray. Initial SDS Microarray – Assay Performance Results of the V&V head-to-head study for the ...

Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 9,230,770 ordinary shares at a price to the public of $6.50 per share. The net proceeds to the Company from this offering are expected to be approximately $56.1 mi...

Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of its ordinary shares. All of the ordinary shares to be sold in the offering will be offered by the Company. In addition, the Company intends to grant the underwriters a ...

Quotient Limited appoints Franz Walt as Chief Executive Officer

JERSEY, Channel Islands, May 29, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt, as its Chief Executive Officer. Mr Walt who retired earlier this year as the President of Siemens Healthineers, Laboratory Diagnostics, is a member of Quotient's Board of Directors, and had been appointed as the interim ...

Quotient Limited Announces Completion of Senior Secured Notes Offering

JERSEY, Channel Islands, July 02, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million aggregate principal amount of its 12% Senior Secured Notes due 2023 (the “Notes”). On June 29, 2018, the Company, completed the second and final closing (the “Second Closing”) of...

Quotient Limited to Participate in the Jefferies 2018 London Healthcare Conference

JERSEY, Channel Islands, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chief Financial Officer, Chris Lindop, will present at the Jefferies 2018 London Healthcare Conference on Tuesday, November 14th, 2018 at 8:40 a.m. GMT (3:40 a.m. Eastern Time). A webcast of the presentation will be available online ...

Quotient Limited Reports Concordance Data from the MosaiQ European Field Trial

Field trial concordance data exceed targeted criteriaPlanned issuance of $36 million in Senior Secured Notes JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported concordance data for the initial MosaiQ blood grouping microarray generated in its European field trial, which exceed the targeted criteria ...

Veritas Signs MOU with Israeli Cannabis Industry Leader IsCann Group Limited

VANCOUVER, British Columbia, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has signed a Memorandum of Understanding (“MOU”) with IsCann Group Limited (“IsCann”) located in Be'er Tuvya, Israel with the aim of establishing, maintaining, and expanding business in the Canad...

Quotient Limited to Participate in the 2018 Cantor Fitzgerald Global Healthcare Conference

JERSEY, Channel Islands, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Franz Walt, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 3rd, 2018 at 4:00 p.m. EDT at The InterContinental New York Barclay Hotel, in New York, NY.  ...

Quotient Limited Announces Receipt of Consents to Modifications to the Company’s Senior Secured Notes

JERSEY, Channel Islands, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the receipt of consents from the holders of its Senior Secured Notes (the Notes) to certain amendments (the Proposed Amendments) to the indenture governing the Notes (the Indenture).    Franz Walt, Quotient’s Chief Executive Offi...

BeiGene Attends Hearing Before the Listing Committee of the Stock Exchange of Hong Kong Limited

CAMBRIDGE, Mass. and BEIJING, China, July 20, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that it attended a hearing before the Listing Committee of the Stock Exchange of Hong Kong Limited (“HKEx...

Quotient Limited to Report Fiscal Second Quarter 2019 Financial Results and Host Conference Call

JERSEY, Channel Islands, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2018, will be released before market open on Monday, November 5, 2018. Quotient will host a conference call to discuss its second quarter financial results at 8:00 a.m. Easte...

Quotient Limited to Report Fiscal First Quarter 2019 Financial Results and Host Conference Call

JERSEY, Channel Islands, July 24, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2018, will be released after market close on Monday, August 6, 2018. Quotient will host a conference call on Tuesday, August 7, 2018 at 8:00 a.m. Eastern Time to discuss its f...

Genetic Technologies Announces Proposed Joint Venture with Beijing Zishan Health Consultancy Limited

MELBOURNE, Australia, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has signed a Heads of Agreement (Agreement) with Beijing Zishan Health Consultancy Limited (Zishan). The Agreement pr...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks